Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 02 October 2012 | By Alexander Gaffney, RAC
The Department of Justice (DOJ) has filed a motion to dismiss a lawsuit brought against the US Food and Drug Administration (FDA) by several current and former agency employees after FDA allegedly spied on their whistleblowing activities to members of Congress and other oversight agencies.
DOJ's motion, filed on 1 October-almost exactly a year after the case was first filed-seeks dismissal based on a "lack of jurisdiction."
Bloomberg explains DOJ argues that any whistleblowing claims must first be reviewed through an administrative process run by the Office of Special Counsel (OSC). Before those processes are exhausted, the plaintiffs should not be allowed to seek judicial relief, argues DOJ.
Presiding Justice Robert L. Wilkins did not make any ruling on the motion, giving the plaintiffs, represented by Steven Kohn of the National Whistleblowers Foundation, time to respond.
If the motion is granted, it could prove to be more of a delaying tactic than anything else. In previous statements, OSC-an Executive Branch agency charged with protecting whistleblowers-has seemed to side with the FDA whistleblowers.
OSC's head, Special Counsel Carolyn Lerner, wrote in a February 2012 press release that she believed FDA's activities could potentially, "Dissuade employees from making important disclosures," and may have broken the law. A follow-up guidance released in June 2012 by the agency seemed to again take aim at FDA, calling on federal agencies to, "Heed whistleblower rights" when monitoring potentially protected activities.
The case is Paul T. Hardy v. Jeffery E. Shuren, case number 1:2011cv0139.
Tags: Kohn, NWC, National Whistleblowers Council, Reviewers, Whistleblowers, Taylor, FDA Nine, Shuren, Lawsuit, Latest News, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.